Takeda Peru is building a product portfolio based on local need, focusing on gastroenterology, cardiology, metabolism, oncology and respiratory diseases. The company will initially focus on Zurcal (pantoprazole), Riopan (Magaldrate + Dimeticone) Faktu (Policresulen, Cinchocaine hydrochloride), and Albothyl (Policresulen).
Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He joins the company from Takeda Colombia, where he headed the Takeda sales and marketing organization following the acquisition of Farmacol Laboratories. He will lead the start-up team, which will grow as the company expands its portfolio and enters new therapeutic areas.
"The launch of our subsidiary in Peru reinforces Takeda's position in Latin America and will enable us to meet the diverse healthcare needs of the population. We have an established product portfolio that will give us a strong starting point, and we look forward to launching our novel medicines into the market," said Norbert Oppitz, senior vice president, Latin America, at Takeda. "This investment further demonstrates our commitment to Latin America and its growth potential."
Takeda also has a presence in Brazil, Mexico, Argentina, Venezuela, Colombia, and Ecuador, and is looking at opportunities to further expand in the region. According to IMS Market Prognosis, pharmaceutical sales in these countries totaled $60 billion in 2012 and are expected to grow at a compound annual rate of 12.5% between 2013 and 2017.